Epitalon: what a 2025 molecular review could — and could not — conclude

Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide modeled on pineal extracts associated with the Khavinson group. Online it is sold as a telomerase or “fountain of youth” peptide.

What the 2025 review gathered

The *IJMS* overview summarizes in-vitro, animal and in-silico work: effects on melatonin-related pathways, antioxidant enzymes, immune markers and telomerase activity in experimental systems. The authors also note that physico-chemical and structural studies are limited, and that it is unclear whether proposed mechanisms are complete.

What is still missing

There is no large, independently replicated, Western randomized trial showing that epitalon extends healthspan or treats a disease in people. In July 2026, FDA compounding reviewers separately argued against listing epitalon as a bulk substance for compounding — a regulatory opinion, not a clinical trial, but a reminder that popularity is not approval.

Bottom line

Evidence ladder: Animal (with older, hard-to-verify human reports outside standard trial registries). A 2025 review can organize the lab story. It cannot convert that story into a human longevity result.